Il-6 detection based early diagnosis and prediction of systematic inflammatory response syndrome and sepsis in asymptomatic patients

Abstract

Methods, systems and kits for the early diagnosis or prediction of systemic inflammatory response syndrome (SIRS) including sepsis in asymptomatic patients, such as patients undergoing a surgical intervention, are provided. Some embodiments include a method and system for the detection or diagnosis of SIRS, or detection or diagnosis of a risk to suffer from or develop SIRS, in an asymptomatic patient comprising the steps of determining the level of IL-6 (or a variant thereof) in a sample from the patient; comparing the level of IL-6 (or a variant thereof) to a reference level; detecting or diagnosing SIRS or diagnosing a risk to suffer from or develop SIRS, wherein the sample is isolated at least 2 times at short intervals and the determining and comparing steps are both repeated for each sample. Also provided are methods, systems and kits for therapy monitoring and mortality prediction.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of International Application No. PCT / EP2011 / 001006, filed Mar. 2, 2011, which claims the benefit of European Patent Application No. 10002190.6, filed Mar. 2, 2010, the disclosures of which are hereby incorporated by reference in their entirety.BACKGROUND OF THE DISCLOSURE[0002]Systemic inflammatory response (SIRS) and sepsis represent a common and devastating syndrome that is increasing in frequency around the world. SIRS and sepsis are among the most frequent causes of death in intensive care patients.[0003]In 1991, the American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) provided a conceptual and practical framework to define the systemic inflammatory response to infection (American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in seps...

AI Technical Summary

Benefits of technology

The patent provides a method for early diagnosis and prediction of systemic inflammatory response syndrome (SIRS) or sepsis in asymptomatic patients by measuring the level of IL-6 in a sample from the patient and comparing it to a reference level. This allows for the detection and diagnosis of SIRS or sepsis risk before the onset of clinical symptoms. The method can be used in patients undergoing surgery or other invasive treatments, and can also be repeated at short intervals to monitor the risk over time. The patent also provides a computer program and a kit for carrying out the method. Overall, the patent provides a sensitive and early tool for identifying patients at risk for SIRS or sepsis, allowing for early intervention and improved outcomes.

Problems solved by technology

Prior to this time, various terminologies were used interchangeably, leading to much confusion.

However, no current methods exist for diagnosing SIRS and sepsis, or for predicting the risk to suffer from or to develop SIRS and sepsis, prior to the onset of such generally recognized clinical signs and symptoms of SIRS and sepsis (for example, in an asymptomatic patient).

Images